| Name | Title | Contact Details |
|---|
Extend your prescription and reorder lenses in just 5 minutes without the doctor`s visit.
Make a difference—in your life and in the world—with a rewarding career at Gillette Children`s Specialty Healthcare. Gillette is a Twin Cities Top Workplace and a National Top Workplace. We offer competitive pay, a strong benefits package and flexible schedules. Plus we give employees something that sets us apart: a chance to take part in our mission. Come to work for Gillette, and you`ll improve the lives of countless children and adults who have disabilities or complex medical conditions. Each year, we see more patients and add more services. That growth enabled us to increase our workforce by more than 30 percent during the past five years. As we continue expanding, you`ll have many chances to learn new skills and advance your career. You`ll also collaborate with teams of caring professionals who are committed to making the world a better place.
Overlook House is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Excerpta Medica is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.